EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA


Phase 4 Results

Eligibility Criteria

Inclusion Criteria

-Clinical diagnosis of ischaemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Symptoms must be distinguishable from an episode of generalised ischaemia (i.e. syncope), seizure, or migraine disorder.
Main inclusion criteria:
- Patients at risk of stroke who have had transient ischaemia of the brain or completed ischaemic stroke due to thrombosis
- Symptoms of ischaemic attack began less than 24 hours prior to study medication start, are to be present for at least 30 minutes and have not significantly improved before start of treatment
- Patients are eligible for platelet inhibiting treatment
- National Institute of Health Stroke Scale (NIHSS) between 5 and 20 (at pre-screening and screening)
- Actual Modified Rankin Scale (mRS) (at baseline) is worse than retrospective mRS (before stroke)
- A contraindication for stroke lysis is given
- Patients are able to give (at least oral) informed consent and to swallow either medication

Exclusion Criteria

- Hypersensitivity to any of the components of the product or salicylates.
- Patients with active gastric or duodenal ulcers or with bleeding disorders.
- Pregnancy during the third trimester.
- Lysis therapy.
- A platelet inhibiting therapy with Acetylsalicylic Acid (ASA) doses of more than 100 mg per day, or with clopidogrel of any dose has been planned or started.
- Time of onset of stroke symptoms is unknown (when a stroke happened during night-/sleeping time, bedtime is assumed as time of onset)